Anticorps Polyclonal de lapin anti-Dysadherin

• Phare
• Validé par KD/KO

Dysadherin Polyclonal Antibody for IHC, WB, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris et plus (1)

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

Publications

5

N° de cat : 12166-1-AP

Synonymes

dysad, Dysadherin, FXYD5, HSPC113, IWU 1, IWU1, KCT1, OIT2, PRO6241, RIC, UNQ2561/PRO6241

---

Galerie de données de validation

• 

  WB analysis of mouse small intestine using 12166-1-AP

  mouse small intestine tissue were subjected to SDS PAGE followed by western blot with 12166-1-AP (Dysadherin antibody) at dilution of 1:500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of human placenta using 12166-1-AP

  human placenta tissue were subjected to SDS PAGE followed by western blot with 12166-1-AP (Dysadherin antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human kidney using 12166-1-AP

  Immunohistochemical analysis of paraffin-embedded human kidney using 12166-1-AP (Dysadherin antibody) at dilution of 1:50 (under 10x lens).

• 

  IHC staining of human kidney using 12166-1-AP

  Immunohistochemical analysis of paraffin-embedded human kidney using 12166-1-AP (Dysadherin antibody) at dilution of 1:50 (under 40x lens).

• 

  IHC staining of human cervical cancer using 12166-1-AP

  Immunohistochemical analysis of paraffin-embedded human cervical cancer using 12166-1-AP (Dysadherin antibody) at dilution of 1:100 (under 10x lens).

• 

  IHC staining of human cervical cancer using 12166-1-AP

  Immunohistochemical analysis of paraffin-embedded human cervical cancer using 12166-1-AP (Dysadherin antibody) at dilution of 1:100 (under 40x lens).

---

Applications testées

• Résultats positifs en WB: tissu d'intestin grêle de souris, tissu placentaire humain
• Résultats positifs en IHC: tissu rénal humain, tissu de cancer du col de l'utérus humain; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:500-1:2400
• Immunohistochimie (IHC): IHC : 1:20-1:200

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Applications publiées

• KD/KO: See 2 publications below
• WB: See 4 publications below
• IHC: See 1 publications below

Informations sur le produit

12166-1-AP cible Dysadherin dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Réactivité citée: rat, Humain, souris
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: Dysadherin Protéine recombinante Ag2808
• Nom complet: FXYD domain containing ion transport regulator 5
• Masse moléculaire calculée: 178 aa, 19 kDa
• Poids moléculaire observé: 24 kDa
• Numéro d’acquisition GenBank: BC009642
• Symbole du gène: FXYD5
• Identification du gène (NCBI): 53827
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS avec azoture de sodium à 0,02 % et glycérol à 50 % pH 7,3
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

Dysadherin, also known as FXYD5 (FXYD domain containing ion transport regulator 5), is a cancer-associated cell membrane glycoprotein which belongs to the FXYD family. The FXYD family, which contains seven members, are tissue specific regulators of the Na,K-ATPase. Dysadherin is involved in down-regulation of E-cadherin, which plays important roles in tumor development and metastasis. It is present in spleen, lung, skeletal muscle, and testis. Increased expression of dysadherin has been associated with increased cell motility and metastatic potential.

Publications

Species	Application	Title
		Int J Oncol; A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.; Authors - Yang Bai
human	WB,IHC	Cell Transplant; Development and Clinical Validation of a Seven-Gene Prognostic Signature Based on Multiple Machine Learning Algorithms in Kidney Cancer.; Authors - Mi Tian
rat	WB	Bioengineered; FXYD domain containing ion transport regulator 5 (FXYD5) silencing promotes cell viability and alleviates inflammatory response in cerulein-induced AR42J cells by blocking JAK2/STAT3 signaling pathway.; Authors - Licheng Ding ; KD Validated
human	WB	Biochimie; Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer; Authors - Takamasa Hotta ; KO Validated
human,mouse	WB	Mol Biotechnol; miR-1180 Targets FXYD5 to Regulate Pancreatic Cancer Cells Migration and Invasion; Authors - Hongmin Xie

Produits associés

E-cadherin Polyclonal antibody

20874-1-AP

Phospholemman/FXYD1 Polyclonal antibody

13721-1-AP

FXYD2 Polyclonal antibody

11198-1-AP

FXYD3 Polyclonal antibody

15853-1-AP

FXYD6 Polyclonal antibody

15805-1-AP

FXYD4 Polyclonal antibody

11966-1-AP

FXYD7 Polyclonal antibody

11465-1-AP